Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways

Haim Werner; Lena Lapkina-Gendler; Laris Achlaug; Karthik Nagaraj; Lina Somri; Danielle Yaron-Saminsky; Metsada Pasmanik-Chor; Rive Sarfstein; Zvi Laron; Shoshana Yakar

doi:10.3390/cells8060596

Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways

Haim Werner, Lena Lapkina-Gendler, Laris Achlaug, Karthik Nagaraj, Lina Somri, Danielle Yaron-Saminsky, Metsada Pasmanik-Chor, Rive Sarfstein, Zvi Laron, Shoshana Yakar

Research output: Contribution to journal › Review article › peer-review

Abstract

Laron syndrome (LS), or primary growth hormone resistance, is a prototypical congenital insulin-like growth factor 1 (IGF1) deficiency. The recent epidemiological finding that LS patients do not develop cancer is of major scientific and clinical relevance. Epidemiological data suggest that congenital IGF1 deficiency confers protection against the development of malignancies. This ‘experiment of nature’ reflects the critical role of IGF1 in tumor biology. The present review article provides an overview of recently conducted genome-wide profiling analyses aimed at identifying mechanisms and signaling pathways that are directly responsible for the link between life-time low IGF1 levels and protection from tumor development. The review underscores the concept that ‘data mining’ an orphan disease might translate into new developments in oncology.

Original language	English (US)
Article number	596
Journal	Cells
Volume	8
Issue number	6
DOIs	https://doi.org/10.3390/cells8060596
State	Published - 2019

Keywords

Cancer protection
Growth hormone receptor (GH-R)
IGF1 receptor (IGF1R)
Insulin-like growth factor 1 (IGF1)
Laron syndrome
Thioredoxin-interacting protein (TXNIP)

ASJC Scopus subject areas

General Medicine

Access to Document

10.3390/cells8060596

Cite this

@article{7724a3b3dd52481eb9c7f519b6df69f6,

title = "Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways",

abstract = "Laron syndrome (LS), or primary growth hormone resistance, is a prototypical congenital insulin-like growth factor 1 (IGF1) deficiency. The recent epidemiological finding that LS patients do not develop cancer is of major scientific and clinical relevance. Epidemiological data suggest that congenital IGF1 deficiency confers protection against the development of malignancies. This {\textquoteleft}experiment of nature{\textquoteright} reflects the critical role of IGF1 in tumor biology. The present review article provides an overview of recently conducted genome-wide profiling analyses aimed at identifying mechanisms and signaling pathways that are directly responsible for the link between life-time low IGF1 levels and protection from tumor development. The review underscores the concept that {\textquoteleft}data mining{\textquoteright} an orphan disease might translate into new developments in oncology.",

keywords = "Cancer protection, Growth hormone receptor (GH-R), IGF1 receptor (IGF1R), Insulin-like growth factor 1 (IGF1), Laron syndrome, Thioredoxin-interacting protein (TXNIP)",

author = "Haim Werner and Lena Lapkina-Gendler and Laris Achlaug and Karthik Nagaraj and Lina Somri and Danielle Yaron-Saminsky and Metsada Pasmanik-Chor and Rive Sarfstein and Zvi Laron and Shoshana Yakar",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

doi = "10.3390/cells8060596",

language = "English (US)",

volume = "8",

journal = "Cells",

issn = "2073-4409",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "6",

}

TY - JOUR

T1 - Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways

AU - Werner, Haim

AU - Lapkina-Gendler, Lena

AU - Achlaug, Laris

AU - Nagaraj, Karthik

AU - Somri, Lina

AU - Yaron-Saminsky, Danielle

AU - Pasmanik-Chor, Metsada

AU - Sarfstein, Rive

AU - Laron, Zvi

AU - Yakar, Shoshana

PY - 2019

Y1 - 2019

N2 - Laron syndrome (LS), or primary growth hormone resistance, is a prototypical congenital insulin-like growth factor 1 (IGF1) deficiency. The recent epidemiological finding that LS patients do not develop cancer is of major scientific and clinical relevance. Epidemiological data suggest that congenital IGF1 deficiency confers protection against the development of malignancies. This ‘experiment of nature’ reflects the critical role of IGF1 in tumor biology. The present review article provides an overview of recently conducted genome-wide profiling analyses aimed at identifying mechanisms and signaling pathways that are directly responsible for the link between life-time low IGF1 levels and protection from tumor development. The review underscores the concept that ‘data mining’ an orphan disease might translate into new developments in oncology.

AB - Laron syndrome (LS), or primary growth hormone resistance, is a prototypical congenital insulin-like growth factor 1 (IGF1) deficiency. The recent epidemiological finding that LS patients do not develop cancer is of major scientific and clinical relevance. Epidemiological data suggest that congenital IGF1 deficiency confers protection against the development of malignancies. This ‘experiment of nature’ reflects the critical role of IGF1 in tumor biology. The present review article provides an overview of recently conducted genome-wide profiling analyses aimed at identifying mechanisms and signaling pathways that are directly responsible for the link between life-time low IGF1 levels and protection from tumor development. The review underscores the concept that ‘data mining’ an orphan disease might translate into new developments in oncology.

KW - Cancer protection

KW - Growth hormone receptor (GH-R)

KW - IGF1 receptor (IGF1R)

KW - Insulin-like growth factor 1 (IGF1)

KW - Laron syndrome

KW - Thioredoxin-interacting protein (TXNIP)

UR - http://www.scopus.com/inward/record.url?scp=85079877135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079877135&partnerID=8YFLogxK

U2 - 10.3390/cells8060596

DO - 10.3390/cells8060596

M3 - Review article

AN - SCOPUS:85079877135

SN - 2073-4409

VL - 8

JO - Cells

JF - Cells

IS - 6

M1 - 596

ER -

Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this